Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 113
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 109
Avatrombopag (Doptelet) increases platelet production by mimicking the action of endogenous thrombopoietin (TPO), activating TPO receptors, and promot···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 112
Avatrombopag (Doptelet) has different dosages and precautions for patients with chronic liver disease and chronic immune thrombocytopenic purpura. It ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 111
Avatrombopag (Doptelet) is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that effectively increases preoperative platelet levels in ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 113
When taking avatrombopag (Doptelet), serious side effects such as bleeding gums and nosebleeds, and abnormal weight gain or loss may occur; milder sid···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 109
On May 21, 2018, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) tablets for the treatment of thrombocytopenia (low plate···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 107
On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved the expansion of the indication for avatrombopag (Doptelet) to include the trea···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 109
On July 25, 2025, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) for the treatment of thrombocytopenia in pediatric pati···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 124
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 115
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 108
The price of entrectinib fluctuates depending on the strength, purchase channel, and region. The original brand-name drug may be more expensive, while···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 116
The price of entrectinib varies depending on the region, health insurance policy, dosage, and purchase channel. The specific monthly treatment cost ne···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 109
IndicationsCrizotinib, also known as XALKORI, is indicated for the treatment of:ALK‑positive or ROS1‑positive metastatic non‑small cell lung cancer (N···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 113
Indications and Mechanism of ActionCrizotinib is indicated for patients with ALK‑positive locally advanced or metastatic non‑small cell lung cancer (N···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 120
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos



